Abstract
Background. Unlike cytomegalovirus (CMV) infection and aging, human immunodeficiency virus (HIV) decreases the proportion of CD28 -CD8+ T cells expressing CD57. Whether this abnormality predicts mortality in treated HIV infection and can be reversed by early antiretroviral therapy (ART) remains unknown. Methods. We sampled recently HIV-infected individuals (<6 months) and HIV-uninfected controls and compared longitudinal changes in the proportion of CD28-CD8+ T cells expressing CD57 between those who initiated ART early (<6 months) vs later (≥2 years).We also assessed the relationship between this phenotype and mortality in a nested case-control study of ART-suppressed chronically infected individuals. Results. Compared to HIV-uninfected controls (n = 15), individuals who were recently infected with HIV had lower proportions of CD28 -CD8+ T cells expressing CD57 (P < .001), and these proportions increased during ART. The early ART group (n = 33) achieved normal levels, whereas the later ART group (n = 30) continued to have lower levels than HIV-uninfected controls (P = .02). Among 141 ART-suppressed participants in the SOCA study, those in the lowest quartile of CD28-CD8+ T cells expressing CD57 had 5-fold higher odds of mortality than those in the highest quartile (95% CI, 1.6-15.9, P = .007). Conclusions. Abnormally low proportions of CD28-CD8+ T cells expressing CD57 predict increased mortality during treated HIV infection and may be reversed with early ART initiation.
Original language | English (US) |
---|---|
Pages (from-to) | 374-382 |
Number of pages | 9 |
Journal | Journal of Infectious Diseases |
Volume | 210 |
Issue number | 3 |
DOIs | |
State | Published - Aug 1 2014 |
Keywords
- Aging
- Antiretroviral therapy
- CD28
- CD57
- HIV
- Immune activation
- Immunosenescence
- Mortality
ASJC Scopus subject areas
- Immunology and Allergy
- Infectious Diseases